Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies1000
Biocartis
Biocartis is a molecular diagnostics company.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
AccuGenomics
AccuGenomics is a molecular diagnostics company that develops a unique spike-in control technology.
Sector
Subsector
Keywords
Location
Genetic Analysis
Genetic Analysis AS is a company that specializes in molecular diagnostics of gut imbalances.
Sector
Subsector
Keywords
Location
total rounds
total raised
Asuragen
Asuragen is a fully integrated diagnostics company specializing in mRNA-based solutions for molecular oncology and early cancer detection.
Sector
Subsector
Location
total rounds
total raised
M&A Details1
Financials
Funding Rounds7
Number of Funding Rounds
Money Raised
Their latest funding was raised on 22.10.2021. Their latest investor Innogenetics. Their latest round Grant
Biomedical Advanced Research and Development Authority (BARDA)
BARDA develops and purchases vaccines, drugs, therapies, and diagnostic tools for emergencies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors5
Number of lead investors
Number of investors
Innogenetics
Innogenetics NV is a biotechnology company that develops and markets diagnostic products for therapy management and patient health.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
Wheatley Partners
Wheatley Partners is a private equity firm focused on technology-related companies.
Sector
Subsector
Location
count Of Investments
count Of Exists
Biomedical Advanced Research and Development Authority (BARDA)
BARDA develops and purchases vaccines, drugs, therapies, and diagnostic tools for emergencies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Acquisitions1
Oncomark acquired by Cepheid
acquirer
date
type
Oncomark
OncoMark develops companion diagnostic tests to support cancer drug development and improve outcomes for cancer patients.
Sector
Subsector
Keywords
Location
total rounds
total raised
People
Founders3
Steve Young
Mr. Young is responsible for cofounding and developing the product vision for BAM Labs. In his previous role at Digeo, he served as Vice President of Hardware and Operations and responsible for innovation in engineering and manufacturing to drive the development of Digeo’s consumer products. Before Digeo, Mr. Young co-founded Cepheid, where, as lead engineering architect, he ran product development from inception through production. While at Cepheid, Mr. Young developed patented DNA analysis instruments to accurately and quickly diagnose dangerous diseases. Cepheid has become an invaluable biological agent detection system for the U.S. Government’s analysis of Anthrax and other biological warfare agents. In 2000, Mr. Young led Cepheid through a successful initial public offering. His pioneering work in the computer field led to the development of the groundbreaking PowerBook® Duo sub-notebook during his more than ten years at Apple Computer. While there, he managed a team of more than 100 professionals and was responsible for PowerBook Duo’s architecture, engineering and manufacturing. During his tenure, PowerBook won numerous accolades, including Business Week’s prestigious Product of the Year award. Mr. Young also spent six years at the Robotics Institute at Carnegie Mellon University, where he secured his first patents as a research design engineer. He holds more than 30 patents for advanced electronics systems, DNA analysis techniques, robotic hands and other technologies. Mr. Young holds a B.S. in Electrical Engineering from Carnegie Mellon University.
current job
organization founded
Steve Young
Dennis H. Giesing
For over 30 years, Dr. Giesing has served in a variety of senior scientific and leadership roles within large pharmaceutical companies, with the last appointment being Senior Vice President, Lead Optimization at Aventis Pharmaceuticals, Inc. Prior to joining TARIS, Dr. Giesing served as Chief Scientific Officer for Urigen Pharmaceuticals. Earlier pharma positions include Vice President, Global Drug Metabolism & Pharmacokinetics at Aventis, as well as other leadership roles at Hoechst Marion Roussel, Marion Merrell Dow and Marion Laboratories. He earned a B.S. in Chemistry and his Ph.D. in Biochemical Pharmacology from the University of Missouri, Kansas City.
current job
organization founded
Dennis H. Giesing
Allen Northrup
Co-founder, CTO, VP Research at Cepheid.
current job
organization founded
Allen Northrup
Employee Profiles341
Activity
Recent News4
The graph reveals the ratio (%) of positive news articles in a chosen time range